Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/14/?d=1Neue Studien: Europe PMCdeBiosimilars for the Treatment of Moderate to Severe Chronic Plaque Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/biosimilars-for-the-treatment-of-moderate-to-severe-chronic-plaque-psoriasis-r229/Weiterlesen

]]>229Wed, 03 Sep 2025 07:11:26 +0000What Is the Diagnostic Capacity of Existing Severity Scoring Tools for Nail Psoriasis?https://www.psoriasis-news.de/articles.html/1_articles/what-is-the-diagnostic-capacity-of-existing-severity-scoring-tools-for-nail-psoriasis-r228/Weiterlesen

]]>228Wed, 03 Sep 2025 07:11:26 +0000Mitochondrial sirtuins 3, 4 and 5 in patients with psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/mitochondrial-sirtuins-3-4-and-5-in-patients-with-psoriasis-r227/Weiterlesen

]]>227Wed, 03 Sep 2025 07:11:26 +0000Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report.https://www.psoriasis-news.de/articles.html/1_articles/successful-guselkumab-treatment-for-a-psoriasis-patient-experiencing-an-adrenal-crisis-a-case-report-r226/Weiterlesen

]]>226Wed, 03 Sep 2025 06:53:32 +0000The Skin-Brain Axis in Psoriasis and Depression: Roles of Inflammation, Hormones, Neuroendocrine Pathways, Neuropeptides, and the Microbiome.https://www.psoriasis-news.de/articles.html/1_articles/the-skin-brain-axis-in-psoriasis-and-depression-roles-of-inflammation-hormones-neuroendocrine-pathways-neuropeptides-and-the-microbiome-r225/Weiterlesen

]]>225Wed, 03 Sep 2025 06:53:32 +0000Toward Harmonized Recommendations for Psoriatic Arthritis: A Comparative Viewpoint on Global Guidelines.https://www.psoriasis-news.de/articles.html/1_articles/toward-harmonized-recommendations-for-psoriatic-arthritis-a-comparative-viewpoint-on-global-guidelines-r224/ObjectivePsoriatic arthritis (PsA) guidelines aim to provide consistent, evidence-based recommendations. Multiple regional guidelines exist, often based on similar evidence but with different methodologies and contexts. Our aim was to compare recent PsA treatment guidelines from the American College of Rheumatology, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, European Alliance of Associations for Rheumatology, and Pan American League of Associations for Rheumatology, identifying similarities, differences, and opportunities for global harmonization with regional adaptation.

Methods

Narrative comparative review of guideline documents published between 2018 and 2024 by major rheumatology societies was performed. Data on methodology, panel composition, treatment domains, pharmacologic recommendations, and update strategies were extracted and synthesized.

Results

Guidelines share core principles, including domain-based approaches, treat-to-target strategies, and the use of conventional synthetic disease-modifying antirheumatic drugs and biologics. Differences arise from methodological frameworks (eg, GRADE [Grading of Recommendations Assessment, Development, and Evaluation], domain-based, adolopment), stakeholder composition, and explicit consideration of regional drug access.

Conclusion

A hybrid framework combining global core recommendations with modular regional adaptations may optimize resource use, improve guideline sustainability, and maintain local relevance. Living systematic reviews and artificial intelligence could support more timely updates.

Weiterlesen

]]>224Wed, 03 Sep 2025 06:53:32 +0000Long-term Safety and Efficacy of Ixekizumab in Patients With Moderate to Severe Psoriasis – a Systematic Review of Randomised Controlled Trialshttps://www.psoriasis-news.de/articles.html/1_articles/long-term-safety-and-efficacy-of-ixekizumab-in-patients-with-moderate-to-severe-psoriasis-a-systematic-review-of-randomised-controlled-trials-r223/Background This systematic review evaluates the efficacy, safety, and tolerability of ixekizumab (IXE), an anti-IL 17A monoclonal antibody, in treating moderate to severe psoriasis. Methods A comprehensive search of PubMed and Scopus using the terms ‘ixekizumab’ and ‘psoriasis’ was conducted. This study was registered in PROSPERO (CRD42024539975) and followed the PRISMA guidelines for reporting systematic reviews. Inclusion criteria encompassed randomised clinical trials assessing the efficacy and safety/tolerability of ixekizumab for moderate-to-severe psoriasis, published from inception until April 2024. Case reports, conference papers, and observational studies were excluded. A total of 5 studies (6 randomised controlled trials) with 4705 participants met the selection criteria out of 1172 search results. The risk of bias was assessed among the selected studies using the RoBViS tool. Results The standardised dosing regimen of ixekizumab demonstrated superior efficacy compared to placebo in improving Psoriasis Area and Severity Index (PASI) from baseline and Static Physician Global Assessment (sPGA) across most of the included studies. No significant difference in efficacy was observed when comparing ixekizumab with ustekinumab in a survey conducted by Reich et al. Most adverse events were mild, although some serious ones were reported. Conclusion Ixekizumab, a monoclonal antibody approved for treating moderate to severe psoriasis, exhibits a superior safety profile comparable to other biologics used in psoriasis. However, its widespread usage in psoriasis is still relatively less than conventional non-selective immunomodulatory agents.

Weiterlesen

]]>223Wed, 03 Sep 2025 06:53:32 +0000Relative sensitivity and preference of indicators in pharmaceutical trials of psoriasis and psoriatic arthritis.https://www.psoriasis-news.de/articles.html/1_articles/relative-sensitivity-and-preference-of-indicators-in-pharmaceutical-trials-of-psoriasis-and-psoriatic-arthritis-r222/Weiterlesen

]]>222Wed, 03 Sep 2025 06:53:32 +0000Trifolirhizin improves the hyperproliferation and excessive inflammatory response in human HaCaT keratinocytes and ameliorates skin lesions in psoriasis-like mouse models.https://www.psoriasis-news.de/articles.html/1_articles/trifolirhizin-improves-the-hyperproliferation-and-excessive-inflammatory-response-in-human-hacat-keratinocytes-and-ameliorates-skin-lesions-in-psoriasis-like-mouse-models-r221/Weiterlesen

]]>221Wed, 03 Sep 2025 06:53:32 +0000Efficacy of risankizumab across GRAPPA domains in psoriatic arthritis: a pooled analysis of patients from the phase 3 KEEPsAKE 1 and 2 studies.https://www.psoriasis-news.de/articles.html/1_articles/efficacy-of-risankizumab-across-grappa-domains-in-psoriatic-arthritis-a-pooled-analysis-of-patients-from-the-phase-3-keepsake-1-and-2-studies-r220/Weiterlesen

]]>220Wed, 03 Sep 2025 06:53:32 +0000Association Between Alcohol Consumption and Psoriasis: Exploratory Analysis of Crowdsourced Web Search Data in Sweden.https://www.psoriasis-news.de/articles.html/1_articles/association-between-alcohol-consumption-and-psoriasis-exploratory-analysis-of-crowdsourced-web-search-data-in-sweden-r219/Weiterlesen

]]>219Wed, 03 Sep 2025 06:53:32 +0000Validation of Turkish psoriatic arthritis screening tool for psoriatic arthritis: A cross-sectional comparative studyhttps://www.psoriasis-news.de/articles.html/1_articles/validation-of-turkish-psoriatic-arthritis-screening-tool-for-psoriatic-arthritis-a-cross-sectional-comparative-study-r218/No abstract supplied.

Weiterlesen

]]>218Wed, 03 Sep 2025 06:53:32 +0000Network pharmacology and Mendelian randomization analysis of Xiao Bi decoction in treating psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/network-pharmacology-and-mendelian-randomization-analysis-of-xiao-bi-decoction-in-treating-psoriasis-r217/No abstract supplied.

Weiterlesen

]]>217Wed, 03 Sep 2025 06:53:32 +0000Generalized Pustular Psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/generalized-pustular-psoriasis-r216/Weiterlesen

]]>216Sun, 24 Aug 2025 17:56:41 +0000Composite Outcome Measures for Psoriatic Arthritis: Project Updates 2024.https://www.psoriasis-news.de/articles.html/1_articles/composite-outcome-measures-for-psoriatic-arthritis-project-updates-2024-r215/Weiterlesen

]]>215Sun, 24 Aug 2025 17:56:41 +0000Causal Effect of Plasma Fatty Acid Profiles on Psoriasis Risk: Genetic Evidence from a Mendelian Randomization Study.https://www.psoriasis-news.de/articles.html/1_articles/causal-effect-of-plasma-fatty-acid-profiles-on-psoriasis-risk-genetic-evidence-from-a-mendelian-randomization-study-r214/Weiterlesen

]]>214Sun, 24 Aug 2025 17:56:41 +0000Characterising Alternative Diagnoses to Psoriatic Arthritis in a Rheumatology-Dermatology Combined Clinic.https://www.psoriasis-news.de/articles.html/1_articles/characterising-alternative-diagnoses-to-psoriatic-arthritis-in-a-rheumatology-dermatology-combined-clinic-r213/Weiterlesen

]]>213Sun, 24 Aug 2025 17:56:41 +0000Clinical efficacy of 308 nm excimer laser irradiation combined with 0.1% tacrolimus ointment in the treatment of plaque-type psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/clinical-efficacy-of-308%C2%A0nm-excimer-laser-irradiation-combined-with-01-tacrolimus-ointment-in-the-treatment-of-plaque-type-psoriasis-r212/Weiterlesen

]]>212Sun, 24 Aug 2025 17:56:41 +0000Beyond Skin Clearance: Personalized Strategies for DLQI Improvement in Psoriasis -Insights From a Shanghai Prospective Cohort.https://www.psoriasis-news.de/articles.html/1_articles/beyond-skin-clearance-personalized-strategies-for-dlqi-improvement-in-psoriasis-insights-from-a-shanghai-prospective-cohort-r211/IntroductionPsoriasis is a chronic immune-mediated disease that significantly impacts patients clinically and psychologically. Physician-assessed severity measures, including Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Physician Global Assessment (PGA), often fail to capture patient-reported outcomes, particularly when clinical improvement and perceived quality-of-life gains are misaligned.

Purpose

To clarify the association between clinical improvements and Dermatology Life Quality Index (DLQI) outcomes, identify predictors of substantial DLQI improvement (≥90% reduction), and explore reasons for suboptimal DLQI responses in patients achieving skin clearance.

Methods

In this 12-week prospective study, 551 psoriasis patients were enrolled at Shanghai Skin Diseases Hospital. Data on demographics, clinical severity (PASI, BSA, and PGA), DLQI scores, and treatment modalities were collected. Logistic regression analyses were employed to assess the dose-response relationships between improvements in clinical parameters and DLQI reduction, and to identify factors of suboptimal DLQI improvement among patients achieving significant skin clearance.

Results

Median DLQI improved significantly (8.0 to 3.0) at week 12, with 24.1% of patients achieving ≥90% DLQI reduction. Strong dose-response associations existed between clinical severity improvements (PASI, BSA, PGA) and DLQI gains. PASI75 responders were significantly more likely to achieve substantial DLQI improvement (OR = 2.48, 95% CI: 1.51-4.07). However, only 33.3% of PASI75 achievers reached ≥90% DLQI improvement. Early clinical response (as early as week 4) strongly predicted superior DLQI outcomes. Female sex, older age, lower baseline DLQI scores, and shorter disease duration were associated with achieving high skin clearance but suboptimal DLQI improvement.

Conclusion

Early clinical response effectively predicts substantial DLQI improvement, whereas demographic and disease-related factors help identify patients at risk for suboptimal quality-of-life gains despite significant skin clearance. These insights support personalized therapeutic strategies aimed at improving patient satisfaction beyond skin clearance alone.

Weiterlesen

]]>211Sat, 23 Aug 2025 09:33:52 +0000GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.https://www.psoriasis-news.de/articles.html/1_articles/glp-1-receptor-agonists-emerging-therapeutic-potential-in-psoriasis-management-current-evidence-and-future-outlook-r210/Weiterlesen

]]>210Sat, 23 Aug 2025 09:18:30 +0000Friend or foe? Sebaceous cyst inflammation during ixekizumab therapy in psoriatic arthritis: case based review.https://www.psoriasis-news.de/articles.html/1_articles/friend-or-foe-sebaceous-cyst-inflammation-during-ixekizumab-therapy-in-psoriatic-arthritis-case-based-review-r209/Weiterlesen

]]>209Sat, 23 Aug 2025 09:18:30 +0000Association between metabolic score for visceral fat and psoriasis: findings from NHANES.https://www.psoriasis-news.de/articles.html/1_articles/association-between-metabolic-score-for-visceral-fat-and-psoriasis-findings-from-nhanes-r208/BackgroundPsoriasis is a persistent inflammatory skin condition. Several studies have revealed that obesity significantly contributes to both the initiation and advancement of psoriasis. The metabolic score for visceral fat (METS-VF) represents an innovative measure designed to forecast visceral obesity, integrating factors such as insulin resistance metabolic score, waist-to-hip ratio (WHR), age, and gender. The present study aimed to investigate the association between METS-VF and psoriasis prevalence, using information gathered from the National Health and Nutrition Examination Survey (NHANES).

Methods

This study utilized the data from a nationally representative cohort of 8023 adults from NHANES from 2003-2006 to 2009-2014, of which 234 declared a psoriasis history. Multivariate logistic regression analysis and restricted cubic spline (RCS) analyses were used to investigate the association between METS-VF and psoriasis, followed by subgroup analysis to identify populations that may exhibit higher sensitivity.

Results

After adjusting for confounding variables, the results of the multivariate logistic regression analysis showed a significant positive association between METS-VF and the risk of psoriasis. One-unit increasement in METS-VF corresponded to a 47% rise in psoriasis risk (odds ratio [OR] = 1.47, 95% confidence interval [CI] = 1.10-1.96). Finally, the results were uniform across all subgroups (P for interaction > 0.05). The results from the RCS analysis indicated a notable linear association.

Conclusion

This research indicated that elevated levels of METS-VF are linked to a higher occurrence of psoriasis, suggesting the potential of METS-VF as a predictive anthropometric index for assessing the risk of developing psoriasis.

Weiterlesen

]]>208Sat, 23 Aug 2025 09:18:30 +0000Effects of Acute Time-Restricted Eating on Inflammation in Individuals With Psoriasis: Protocol for a Case-Control, Prospective Study.https://www.psoriasis-news.de/articles.html/1_articles/effects-of-acute-time-restricted-eating-on-inflammation-in-individuals-with-psoriasis-protocol-for-a-case-control-prospective-study-r207/BackgroundPsoriasis is a chronic inflammatory disease associated with multiple comorbidities, including metabolic syndrome and cardiovascular disease. Although specific dietary interventions, such as intermittent fasting and caloric restriction, have been shown to ameliorate inflammation and promote weight loss, the effect of these interventions independent of weight loss remains unclear. Time-restricted eating (TRE), a type of intermittent fasting, limits the daily eating window to a fixed number of hours. Recent studies suggest TRE may improve immune function in individuals with metabolic syndrome and cardiovascular risk factors. A crucial advantage of TRE over other investigated dietary restriction strategies is its reported high adherence rate, making it a more feasible intervention for long-term use. Therefore, exploring the effects of TRE on metabolic and immunological parameters in psoriasis is warranted.

Objective

This study was designed to evaluate the effects of short-term, isocaloric TRE, independent of weight loss, on immune cell function and serum metabolite profiles of volunteers with mild-to-moderate psoriasis compared to healthy individuals.

Methods

This case-control, prospective study was performed on 10 healthy male participants and 10 age-, BMI-, and sex-matched individuals with mild-to-moderate psoriasis. All individuals with psoriasis had stable disease and were being treated with topical therapies without any exposure to immunomodulatory biologics. This study was conducted at the National Institutes of Health Clinical Center. Immune profiles, glucose handling, energy expenditure, and participants' weights were assessed at baseline and after 3 days of TRE following a daily 6-hour eating window and 18-hour fast.

Results

The trial commenced in June 2021 and was completed in February 2023. A total of 20 participants were enrolled-10 with mild-to-moderate psoriasis and 10 age-, BMI-, and sex-matched healthy individuals. As of the time of manuscript submission, data processing is ongoing. Multiomic datasets, including gene expression, surface and intracellular protein levels, and metabolite profiles, are being generated from peripheral blood mononuclear cells, CD4+-enriched T-cells, and serum samples. The integrated bioinformatics analyses will be reported once the data analysis is completed.

Conclusions

This clinical protocol was designed to characterize the effects of short term (3-day) TRE on psoriasis, independent of weight loss, by comparing immune cell regulatory responses between healthy individuals and those with psoriasis. More specifically, we aim to map the molecular pathways activated by TRE and assess how they affect immune cell composition, activation, and metabolism. Additionally, components of the metabolic response to isocaloric TRE are being explored. Insights into how dietary interventions impact metabolism and the immune system will enhance our understanding of the pathogenesis of psoriasis and may reveal new therapeutic avenues for managing this inflammatory condition.

Trial registration

ClinicalTrials.gov NCT04728165; https://clinicaltrials.gov/study/NCT04728165.

Weiterlesen

]]>207Sat, 23 Aug 2025 09:18:30 +0000JNK/c-Jun cascade activation enhances malignant proliferation of psoriatic keratinocytes by regulating ROS levels and mitochondrial membrane potential.https://www.psoriasis-news.de/articles.html/1_articles/jnkc-jun-cascade-activation-enhances-malignant-proliferation-of-psoriatic-keratinocytes-by-regulating-ros-levels-and-mitochondrial-membrane-potential-r206/Weiterlesen

]]>206Sat, 23 Aug 2025 09:18:30 +0000Impact of psoriasis on THA and TKA outcomes: A systematic review.https://www.psoriasis-news.de/articles.html/1_articles/impact-of-psoriasis-on-tha-and-tka-outcomes-a-systematic-review-r205/Weiterlesen

]]>205Sat, 23 Aug 2025 09:18:30 +0000